https://www.forbes.com/sites/joshuacohen/2024/11/05/promising-schizophrenia-drug-cobenfy-will-likely-face-access-challenges
Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action, which is the first for schizophrenia in several decades. Cobenfy targets cholinergic receptors instead of balancing levels of dopamine and serotonin, which is what conventional atypical antipsychotics
Promising Schizophrenia Drug, Cobenfy, Will Face Access Challenges
Published in Business and Uncategorized
More from BusinessMore posts in Business »
- Gold closes week above $2,700, US PCE data in Focus
- Mexican Peso stages late recovery, finishes week down
- US Dollar gives up gains from two year highs, closes the week strong
- Australian Dollar softens as markets digest both Judo and S&P PMIs
- NZD/JPY Price Analysis: Pair tumbles and eyes break of 90.00-92.00 range
- Could Gen AI End Incumbent Firms’ Competitive Advantage?
- Khan Academy: A Case Study in Scaling a Start-Up
- How to Manage an Employee Who Gets on Your Nerves
- Lessons from Jersey, the only place under the British crown that already elects police chiefs
- The Clegg paradox
More from UncategorizedMore posts in Uncategorized »
- Gold closes week above $2,700, US PCE data in Focus
- Mexican Peso stages late recovery, finishes week down
- US Dollar gives up gains from two year highs, closes the week strong
- Australian Dollar softens as markets digest both Judo and S&P PMIs
- NZD/JPY Price Analysis: Pair tumbles and eyes break of 90.00-92.00 range
- Could Gen AI End Incumbent Firms’ Competitive Advantage?
- Khan Academy: A Case Study in Scaling a Start-Up
- How to Manage an Employee Who Gets on Your Nerves
- Lessons from Jersey, the only place under the British crown that already elects police chiefs
- The Clegg paradox